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ABSTRACT 
Delivery across skin is striking due to its easy convenience. However, drug delivery across skin is still a confront in biomedical 
sciences. Over the past few decades, various successful narrative devices and techniques have emerged to optimize drug delivery 
across skin whose barricading behaviour constricts entry of most of the therapeutic agents. Ethosomes are non-invasive delivery 
transporter that enables drugs to reach the deep skin layers and/or the systemic circulation. Although ethosomal systems are 
theoretically sophisticated, they are characterized by simplicity in their preparation, efficacy and safety. A combination that can 
highly inflate their application. Ethosomes are soft, malleable vesicles adapted for enhanced delivery of active agents. This article 
reviews work carried out method of preparation, application and characterization of ethosomal systems. Because of their 
exceptional structure, ethosomes are able to encapsulate and deliver through the skin highly lipophilic molecules such as 
testosterone, cannabinoids and minoxidil as well as cationic drugs such as trihexyphenidil and propranolol. Results obtained in a 
double-blind two-armed randomized clinical study showed that treatment with the ethosomal acyclovir formulation appreciably 
improved all the evaluated parameters. In further work, the ethosomal expertise was broadened to introduce agents into cultured 
cells and microorganisms. Enhanced delivery of bioactive molecules through the skin and cellular membranes by means of an 
ethosomal transporter opens numerous confronts and prospects for the research and future development of novel improved 
therapies. 
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INTRODUCTION 
The impending benefits related to transdermal drug 
delivery are widely reported in the literature 1, 2. Among 
these advantages are compact side effects and prevention 
of first-pass hepatic elimination and intestinal degradation. 
However, percutaneous delivery of most molecules is often 
excluded because of the barrier nature of the skin, which 
functionally impedes the entrance of exogenous materials. 
To overcome this obstruction, various methods of skin 
permeation enhancement described in numerous scientific 
works and patents have been used 3, 4. Human skin has a 
multifunctional role including its major role as a barrier 
against both the outlet of endogenous substances (water) 
and the entrance of xenobiotic material (chemicals and 
drugs). It is regarded as first line of protection in human 
body. The stratum corneum consisting corneocytes mainly 
accounts for the barrier properties of skin 5, 6. From some 
time several aspect have come out which has given 
immense esteem and rapid progress to transdermal 
delivery formulations over conventional formulations 
because  circumvention of variations which appear at 
gastro-intestinal absorption 7, improvement in 
bioavailability of drugs by delivering the active principles 
directly into the systemic circulation, bypassing the hepatic 
metabolism 8, by giving a constant, controlled drug enter 
decreasing the variations in drug plasma levels 9, 
augmentation in patient compliance by providing a 
simplified way of administration, lowest risk of trauma or 
any other injury of tissue. In order to increase the 
permeability of the skin for transdermal delivery of drugs 
several passive as well as active procedure have been 
proposed such as penetration enhancers, vesicles, 
iontophoresis, supersaturated systems, electroporation, 
phonophoresis, use of microneedles and jet injectors, etc. 
Although all the efforts devoted to penetration 
enhancement, only few bioactive agents are currently 
transdermally administered. One of the most utilizable 
methods for drugs’ transport across the skin is the use of 
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vesicle formulation as skin delivery systems. Ethosomes 
are soft, malleable lipid vesicles composed mainly of 
phospholipids, alcohol in relatively high concentration (20-
45%) and water (Fig. 1). Ethosomes were first developed 
by Touitou and her colleagues in 1997 10-12. This 
transporter presents interesting features correlated with 
its ability to permeate whole through the human skin due 
to its high deformability. The physicochemical 
characteristics of ethosomes allow these vesicular 
phospholipids as the vesicle forming component of 
ethosomal system. Phospholipids with various chemical 
structures like phosphatidyl choline, phosphatidyl 
ethanolamine are used at concentrations ranging from 0.5-
10%.
 
 
Figure 1: Structure of ethosomes 13 
Structure of skin  
Stratum corneum is the remotest layer of the epidermis. It 
consists of 10 to 25 layers of dead, elongated, fully 
keratinized corneocytes, which are fixed in a matrix of lipid 
bilayers. It has been exposed that the stratum corneum is 
the main barrier to penetration through the skin. When a 
topical formulation is placed on the skin, the active drug is 
required to penetrate through the stratum corneum into 
the viable tissue (Fig 2). The limiting factor for these 
processes is the slow diffusion through the dead horny 
layer of skin. Stratum corneum behaves as a hydrophobic 
membrane. The rates of permeation of skin by low and high 
molecular weight organic non electrolytes are mostly 
determined within the stratum corneum 14, 15. 
 
 
Figure 2: Structure of skin 16 
COMPOSITION OF ETHOSOMES 
Ethosomes exhibit lipid bilayer like liposomes; however 
they differ from liposomes in terms of composition (high 
content of ethanol). The ethosomes are composed of 
hydroalcoholic or hydro/glycolicphospholipid in which the 
concentration of alcohol is relatively high. Ethosomes may 
contain phospholipids with various chemical structures 
like phosphatidylcholine, phosphatidic acid, 
phosphatidylserine, Phosphatidyl ethanolamine, 
phosphatidyl glycerol, phosphatidyl inositol, alcohol 
(ethanol or isopropyl alcohol), water and propylene glycol 
(or other glycols). Some preferred phospholipids such as 
Phospholipon 90 (PL-90). It is usually employed in a range 
of 0.5-10% w/w. Cholesterol at concentrations ranging 
between 0.1-1% can also be added to the preparation. 
Alcohol, such ethanol and isopropyl alcohol; among glycols, 
propylene glycol and Transcutol are generally used which 
may range from 20 to 50% in the final product. In addition 
to non-ionic surfactants (PEG-alkyl ethers) and cationic 
lipids (cocoamide, POE alkyl amines, dodecylamine, 
cetrimide etc) can be combined with the phospholipids in 
the preparations 17. The concentration of the non-aqueous 
phase (alcohol and glycol combination) may range 
between 22 to 70%. Various additives which are used for 
formulation of ethosomes are listed in the Table 1. 
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Table 1: Different additive employed in formulation of ethosomes 18-22 
Class Example Uses 
Phospholipids  
 
Soya phosphatidyl choline 
Egg phosphatidyl choline 
Dipalmityl phosphatidyl choline 
Distearyl phosphatidyl choline 
It influences on the size,entrapment efficacy, zeta 
potential and penetration properties of the 
vesicles.  
 
Alcohol Ethanol 
Isopropyl alcohol 
For providing the softness for vesicle membrane  
As a penetration enhancer  
Polyglycol Propylene glycol, Transcutol RTM As a skin penetration enhancer 
Cholesterol  Cholesterol  For providing the stability to vesicle membrane  
Edge activators  N-DMSO ,Tween[22], Span  Enhances skin permeability 
Dye  Rhodamine-123  
Rhodamine red Fluorescene  
Isothiocynate(FITC)  
6 – Carboxy fluorescence  
For characterization study  
others  Dicetyl phosphate  Prevent aggregation of vesicles 
Vehicle  Carbopol D-934, HPMC  As a gel former  
 
Advantage of ethosomal drug delivery system 
In comparison to other transdermal & dermal delivery 
systems, Ethosomal drug delivery systems contain several 
advantages. Few advantages are; 
1. It contains non-toxic raw material in formulation. 
2. Delivery of large molecules (peptides, protein 
molecules) is possible. 
3. Enhanced permeation of drug through skin for 
transdermal drug delivery. 
4. High patient compliance: The ethosomal drug is 
administrated in semisolid form (gel or cream) hence 
producing high patient compliance. 
5. Simple method for drug delivery in comparison to 
Iontophoresis and Phonophoresis and other 
complicated methods. 
6. Ethosomal drug delivery system can be applied widely 
in Pharmaceutical, Veterinary, Cosmetic fields. 
7. Ethosomal system acts as delivery system for a 
fluorescent probe (quantum dots) to the skin, in terms 
of quantity and depth.  
8. Ethosomes show highest transdermal flux enhances 
the permeation of drug through deeper layers of skin.   
9. Due to intense research toxicological profiles of the 
ethosome components are well-evaluated and 
documented in the scientific literature thus the 
ethosome technology has no large-scale drug 
development risk 
10. The ethosomal system is passive, non-invasive and is 
available for immediate  commercialization 
11. Drugs entrapped in ethosome having different 
physicchemical characteristics and olecular sizes are 
showing high degree of permeation compare to other 
nano-carriers. 
12. Ethosomes improve skin delivery under occlusive and 
non-occlusive conditions.  
13. High market attractiveness for products with 
proprietary technology. Relatively simple to 
manufacture with no complicated technical 
investments required for production of Ethosomes 23. 
Disadvantages of ethosomal drug delivery 
1. Ethosomes with poor shells may clump together and 
leads to precipitation.  
2. Adequate solubility of the drug in both lipophilic and 
aqueous environments to reach dermal 
microcirculation and gain access to the systemic 
circulation. 
3. Skin irritation or dermatitis due to excipients and 
enhancers of drug delivery systems. 
4. Ethosomal administration is not a means to achieve 
rapid bolus type drug input, rather it usually designed 
to offer slow, sustained drug delivery. 
5. Drugs that require high blood levels cannot be 
administered –limited to only potent drugs (daily dose 
-10mg or less)  
6. Poor practical yield.  
7. Transfer of ethosomes from organic to aqueous layer 
leads to loss of product  
8. The molecular size of the drug should be reasonable 
that it should be absorbed percutaneously. 
9. Adhesive may not adhere well to all types of skin. 
10. May not be economical. 
11. In case if shell locking is ineffective then the 
ethosomes may coalescence and fall apart on transfer 
into water 24-29. 
MECHANISM OF DRUG PENETRATION 
The mechanism of penetration of the ethosomes involves 
two concurrent mechanisms of ethanol effect and 
ethosome effect on the stratum corneum lipid bilayer 
Because of the use of ethanol in the preparation of the 
ethosomes, the deformability of the vesicles is increased. 
The high alcohol content is expected to partially extract the 
stratum corneum lipids (Fig 3).These processes are 
responsible for increasing inter and intracellular 
permeability of ethosomes. The ultra deformable vesicles 
can move in the path of the disordered stratum corneum 
and finally release drug in the deeper layers of the skin 30. 
 Ethosomes effect 
 Ethanol effect 
Ethosomes effect 
Increased cell membrane lipid fluidity caused by the 
ethanol of ethosomes results increased skin permeability. 
So the ethosomes permeates very easily inside the deep 
skin layers, where it got fused with skin lipids and releases 
the drugs into deep layer of skin 
Ethanol effect 
Ethanol acts as a penetration enhancer through the skin. 
The mechanism of its penetration enhancing effect is well 
known. Ethanol penetrates into intercellular lipids and 
increases the fluidity of cell membrane lipids and decrease 
the density of lipid multilayer of cell membrane 31. 
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Figure 3: Mechanism of action of ethosomes for skin delivery 13 
 
METHODS OF PREPARATION 
Ethosomes can be prepared and formulated by four 
methods. All methods are sound simple and convenient 
because no need of complex processes or sophisticated 
instruments. 
Cold method 
This is the most common method utilized for the 
preparation of ethosomal formulation. In this method 
phospholipid, drug and other lipid materials are dissolved 
in ethanol in a covered vessel at room temperature by 
vigorous stirring with the use of mixer. Propylene glycol or 
other polyol is added during stirring. This mixture is 
heated to 300C in a water bath. The water heated to 300C 
in a separate vessel is added to the mixture, which is then 
stirred for 5 min in a covered vessel. The vesicle size of 
ethosomal formulation can be decreased to desire extend 
using sonication 32 or extrusion 33 method. Finally, the 
formulation is stored under refrigeration 34. 
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Hot method 
In this method phospholipid is dispersed in water by 
heating in a water bath at 400C until a colloidal solution is 
obtained. In a separate vessel ethanol and propylene glycol 
are mixed and heated to 400C. Once both mixtures reach 
400C, the organic phase is added to the aqueous one. The 
drug is dissolved in water or ethanol depending on its 
hydrophilic/ hydrophobic properties. The vesicle size of 
ethosomal formulation can be decreased to the desire 
extent using probe sonication or extrusion method 35. 
 
Classic method  
The phospholipid and drug are dissolved in ethanol and 
heated to 30°C±1°C in a water bath. Double distilled water 
is added in a fine stream to the lipid mixture, with constant 
stirring at 700rpm, in a closed vessel. The resulting vesicle 
suspension is homogenized by passing through a 
polycarbonate membrane using a hand extruder for three 
cycles 36. 
Mechanical dispersion method 
Soya phosphotidylcholine is dissolved in a mixture of 
chloroform: methanol in round bottom flask (RBF). The 
organic solvents are removed using rotary vacuum 
evaporator above lipid transition temperature to form a 
thin lipid film on wall of the RBF. Finally, traces of solvent 
mixture are removed from the deposited lipid film by 
leaving the contents under vacuum overnight. Hydration is 
done with different concentration of hydroethanolic 
mixture containing drug by rotating the RBF at suitable 
temperature 36. 
CHARACTERIZATION OF ETHOSOMES 37 
Vesicle size and Zeta potential 
Particle size and zeta potential can be determined by 
dynamic light scattering (DLS) using a computerized 
inspection system and photon correlation spectroscopy 
(PCS). 
Vesicle shape 
Visualization of ethosomes can be done using transmission 
electron microscopy (TEM) and by scanning electron 
microscopy (SEM). Visualization by electron microscopy 
reveals a thosomal formulation exhibited vesicular 
structure 300-400 nm in diameter. The vesicles seem to be 
alleable as evident by their imperfect round shape. 
Entrapment efficiency 
The entrapment efficiency of drug in ethosomes can be 
measured by the ultracentrifugation technique. The 
chemical nature of the lipid is an important factor in 
determining the EE of drug in the ethosomes because lipid 
which forms bilayer structure holds the drug perfectly. On 
the other hand, the imperfection of the lipid structure could 
offer space to accommodate the drug. The vesicles are 
separated in a high speed cooling centrifuge at 20,000 rpm 
for 90 minutes in the temperature maintained at 4°C. 
Separate the sediment and supernatant liquids determine 
the amount of drug in the sediment by lysing the vesicles 
using methanol. 
% Entrapment = Actual content/Theoretical content x 100 
Surface tension measurement 
The surface tension activity of drug in aqueous solution can 
be measured by the ring method in a Du Nouy ring 
tensiometer. 
Surface morphology study 
Different types of lipids influence the surface morphology 
or shape of the particles. Lipid microparticle suspensions 
were deposited on metallic stubs then placed in liquid 
nitrogen and dried under vacuum. The freeze-dried 
microparticles were coated uniformly with gold. It is 
characterized for morphology and surface properties using 
a scanning electron microscope. 
Drug content 
Drug content of the ethosomes can be determined using UV 
spectrophotometer. This can also be quantified by a 
modified high performance liquid chromatographic 
method. 
Transition temperature  
The Transition temperature (T) of vesicular lipids is 
measured in duplicate by DSC in an aluminum pan at a 
heating rate of 10°C per min within a temperature range 
from 20º-300ºC., under a constant nitrogen stream 
Stability studies 
The ability of ethosomal preparations to retain the drug 
(i.e., drug-retentive behavior) can be checked by keeping 
the preparations at different temperatures, i.e., 25 ± 2°C 
(room temperature, RT), 37 ± 2°C and 45 ± 2°C for different 
periods of time (1, 20, 40, 60, 80 and 120 days). The 
ethosomal preparations were kept in sealed vials (10 ml 
capacity) after flushing with nitrogen. The stability of 
ethosomes was also determined quantitatively by 
monitoring size and morphology of the vesicles using DLS 
and TEM. 
Degree of deformability and turbidity 
The degree of deformability of the Ethosomal preparation 
can be performed by extrusion method and the turbidity of 
the preparation can be performed by using nephelometer 
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Skin permeation studies 
Confocal laser scanning microscopy (CLSM) method is used 
to determine the depth of penetration from Ethosomes. 
The ethosomes shows significantly higher skin deposition 
possibly due to combined effect of ethanol and 
phospholipid thus providing a mode for dermal and 
transdermal delivery. 
In vitro drug release study and Drug deposition study 
In vitro drug release study and drug deposition of 
ethosomal preparation can be performed by Franz 
diffusion cell with artificial or biological membrane, 
Dialysis bag diffusion. 
Phospholipid-ethanol interaction 
The Phospholipid-ethanol interaction was studied by using 
Proton decoupled 31P-NMR and Differential Scanning 
calorimetry. 
EVALUATION OF ETHOSOME 38 
Vesicle-skin interaction study by TEM and SEM 
From animals ultra-thin sections were cut (Ultracut, 
Vienna, Austria), collected on formvar coated grids and 
examined under transmission electron microscope. For 
SEM analysis, the sections of skin after dehydration were 
mounted on stubs using an adhesive tape and were coated 
with gold palladium alloy using a fine coat ion sputter 
coater. The sections were examined under scanning 
electron microscope. 
Filter membrane-vesicle interaction study by scanning 
electron microscopy 
Vesicle suspension (0.2 mL) was applied to filter 
membrane having a pore size of 50 nm and placed in 
diffusion cells. The upper side of the filter was exposed to 
the air, whereas the lower side was in contact with PBS 
(phosphate buffer saline solution), (pH 6.5). The filters 
were removed after 1 hour and prepared for SEM studies 
by fixation at 4°C in Karnovsky’s fixative overnight 
followed by dehydration with graded ethanol solutions 
(30%, 50%, 70%, 90%, 95%, and 100% vol/vol in water). 
Finally, filters were coated with gold and examined in SEM. 
Vesicle-skin interaction study by fluorescence 
microscopy 
Fluorescence microscopy was carried according to the 
protocol used for TEM and SEM study. Paraffin blocks are 
used, were made, 5-μm thick sections were cut using 
microtome (Erma optical works, Tokyo, Japan) and 
examined under a fluorescence micro Cytotoxicity Assay 
MT-2 cells (Tlymphoid cell lines) were propagated in 
Dulbecco's modified Eagle medium (HIMEDIA, Mumbai, 
India) containing 10% fetal calf serum, 100 U/mL 
penicillin, 100 mg/mL streptomycin, and 2 mmol/L 
Lglutamine at 37°C under a 5% CO2 atmosphere. 
Cytotoxicity was expressed as the cytotoxic dose 50 (CD50) 
that induced a 50% reduction of absorbance at 540nm. 
Skin permeation studies 
The hair of test animals (rats) were carefully trimmed 
short (<2 mm) with a pair of scissors, and the abdominal 
skin was separated from the underlying connective tissue 
with a scalpel. The excised skin was placed on aluminums 
foil, and the dermal side of the skin was gently teased off 
for any adhering fat and/or subcutaneous tissue. The 
effective permeation area of the diffusion cell and receptor 
cell volume was 1.0 cm2 and 10 mL, respectively. The 
temperature was maintained at 32°C ± 1°C. The receptor 
compartment contained phosphate buffer saline solution 
(10 mL of pH 6.5). Excised skin was mounted between the 
donor and the receptor compartment. Ethosomal 
formulation (1.0 mL) was applied to the epidermal surface 
of skin. Samples (0.5 mL) were withdrawn through the 
sampling port of the diffusion cell at 1, 2, 4, 8, 12, 16, 20 & 
24 hour time intervals and analyzed by high performance 
liquid chromatography assay. 
HPLC Assay 
The amount of drug permeated in the receptor 
compartment during in vitro skin permeation experiments 
and in MT-2 cell was determined by HPLC assay. 
Drug uptake studies 
The uptake of drug into MT-2 cells (1×106 cells/mL) was 
performed in 24-well plates (Corning Inc) in which 100 μL 
RPMI medium was added. Cells were incubated with 100 
μL of the drug solution in phosphate buffer saline solution 
(pH 7.4), ethosomal formulation, or marketed formulation, 
and then drug uptake was determined by analyzing the 
drug content by HPLC assay. 
Statistical analysis 
Statistical significance of all the data generated was tested 
by employing ANOVA followed by studentized range test. A 
confidence limit of P < .05 was fixed for interpretation of 
the results using the software PRISM (GraphPad, Version 
2.01, San Diego, CA). 
APPLICATION OF ETHOSOMES 
Ethosomes find its diverse applications in various 
categories of drugs like Antifungal, Antibiotics, Skin 
infections and Cosmetic field. Some are listed as below 
(Table 2). 
 
Table 2 Applications of ethosomes 39, 40 
Principle 
ingredients Formulation Rationale of ethosomal delivery 
Application 
5-aminolevulivic 
acid(ALA) 
5-aminolevulivic 
Acid ethosomes 
Significantly improved the delivery of ALA in the 
inflammatory skin. 
Anti- psoriasis 
Erythromycin 
Erythromycin 
ethosomes 
Ethosomal erythromycin was highly efficient in 
eradicating S. aureus- induced intradermal infections 
Anti bacterial 
Isoeugenol 
Isoeugenol 
ethosomes 
Chemicals (allergen) in vesicular carrier system can 
enhance the sensitizing capacity. 
allergen 
Matrine Matrine ethosomes Improves the percutaneous permeation Anti- inflammatory 
Methotrexate 
Methotrexate 
ethosomes 
Ethosomes showed favourable skin permeation 
characteristic  Anticancer 
Minoxidil 
Minoxidil ethosomes Enhance the penetration and accumulation of minoxidil 
in the skin by Pilosebaceous targeting 
Hair growth 
promoter 
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Testosterone 
Testosterone 
ethosomes 
Testosterone ethosome for Enhanced transdermal 
delivery Steroid hormone 
Trihexyphenidyl 
HCL 
Trihexyphenidyl HCL 
ethosomes 
Increased drug entrapment efficiency, reduced side 
effect and constant systemic levels Anti-parkinsonian 
Acyclovir Acyclovir ethosomes 
Binary combination of the Lipophilic drug ACV-C16 and  
the ethosomes enhanced ACV absorption into 
synergistically the skin Anti-viral 
Azelaic acid 
Azelaic acid 
ethosomes 
Release rate was higher from ethosomes than from 
liposomes Anti- keratinizing 
Bacitracin 
Bacitracin ethosomes Ethosomal enhances intracellular delivery of and 
reduced drug toxicity in the skin 
Polypeptide 
antibacterial 
Colchicine 
Colchicine ethosomes Enhance skin accumulation, prolong release and 
improve the specificity Anti-gout 
Finasteride 
Finasteride 
ethosomes 
Enhanced percutaneous absorption of finasteride 5-a 
reductase inhibitor Anti-Fungal 
Fluconazole 
Fluconazole 
ethosomes enhances the skin permeation 
Anti-Fungal  
Ibuprofen 
Ibuprofen ethosomes Transdermal nanosystem, designed by using an 
ethosomal carrier 
Antipyretic 
Ligustrazine 
Ligustrazine 
ethosomes Ethosome patch enhances the permeation the skin 
Pulmonary 
vasodilator 
Salbutamol 
Salbutamol 
ethosomes Enhanced drug delivery through skin with ethosomes Anti-asthmatic 
Sotalol Sotalol ethosomes Enhances the systemic absorption anti-arrtthmic 
Vitamin A, C, E 
Vitamin A C,E 
ethosomes 
Anti-oxidation of phospholipid was increase due to the 
synergistic interaction of all three together as compare 
to individual use Vitamin 
Stavudine Stavudine ethosomes 
Ethosome increase the transdermal flux, prolong the 
release of Stavudine Antiretroviral40 
 
Marketed product of ethosomes 41, 42 
In 2000, the ethosomes technology began to Commercialize. There are many companies which developed ethosomes 
products (Table 3). 
Table 3: Marketed formulations of ethosomes 
Name of product Uses Manufacturer 
Cellutight EF  Topical cellulite cream, contains a powerful combination of 
ingredients to increase metabolism and break down fat 
Hampden Health, USA 
 
Decorin cream  Anti-aging cream treating, repairing the visible 
aging signs of the skin including wrinkle lines, sagging, age 
spots, loss of elasticity, and hyper pigmentation 
Genome Cosmetics, 
Pennsylvania, US 
Nanominox  First minoxidil containing product, which uses ethosomes. 
Contains 4% Minoxidil, well-known hair growth promoter 
that must be metabolized by sulfation to the active 
compound. 
Sinere, Germany 
Noicellex  Topical anti-cellulite cream  Novel Therapeutic Technologies, Israel 
Skin genuity  Powerful cellulite buster reduces orange peel  Physonics Nottingham, UK 
Supravir cream For the treatment of herpes virus Trima,Israel 
Body Shape Gel executive solidification cellulite education, stretching the 
skin flexible and based on a technology called ethosomes 
Maccabi CARE 
 
Future perspective 
For transdermal delivery of drugs, stratum corneum is the 
main barrier layer for penetration of drug. Various 
methods have been discovered to enhanced skin 
penetration of drugs lipid vehicle based enhancement 
approach has drawn considerable interest in recent past. 
Studies will continue further to improve skin delivery of 
drug using lipid vesicles. Introduction of ethosomes has 
initiated a new area in vesicular research for transdermal 
drug delivery. Different reports show a promising future of 
ethosomes in making transdermal delivery of various 
agents more effective. Further, research in this area will 
allow better control over drug release in vivo, allowing 
physician to make the therapy more effective. Ethosomes 
offers a good opportunity for the non-invasive delivery of 
small, medium and large sized drug molecules. The results 
of the first clinical study of acyclovir-ethosomal 
formulation support this conclusion. Multiliter quantities of 
ethosomal formulation can be prepared very easily. It, 
therefore, should be not before long that the corresponding 
drug formulation would have found their way into clinics 
to be tested for widespread usage. Thus, it can be a logical 
conclusion that ethosomal formulations possess promising 
future in effective dermal/transdermal delivery of 
bioactive agents. 
Patented 
Ethosome was invented and patented by Prof. Elka Touitou 
along with her students of Department of Pharmaceutics at 
the Hebrew University School of Pharmacy 43, 44. 
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Novel Therapeutic Technologies Inc (NTT) of Hebrew 
University has been succeeded in bringing a number of 
products to the market based on ethosome delivery system 
Table 4. 
 
Table 4: Patents claimed for ethosome formulations 45 
Title Inventor Patent no Year Results 
Tretinoin ethosomes gel and 
preparation method thereof  
Hu Chunmei, Liu Yan , 
Wang Jing, Li Rong  
CN104983675 
A 
2015  the prepared tretinoin ethosomes 
gel is an externally-used 
transdermal delivery preparation  
Chinese medicinal ethosome 
gel patch for treating herpes 
zoster and preparation 
method  
Bu Ping; Hu Rong; Chen 
Lin; Wei Rong; Wu 
Huanhuan; Huang Xiaoli  
CN103536700 
(A)  
2014  Easy in medication and convenient 
to use, has a good therapeutic effect, 
quick response,  
Ethosome gel film-coating 
agent with multiple wound 
repair effects and preparation 
method of ethosome gel film-
coating agent 1  
Chen Jie; Huang 
Changping; Zheng 
Maoxin; Nie Kaipin  
CN103893394 
(A)  
2014  The Ethosome entrapped film-
coating agent helps to promote 
healing and nutrition supplying of 
the wound tissue.  
Daptomycin ethosome 
preparation  
Li Chong; Liu Xia; Yin 
Qikun; Wang Xiaoying; 
Chen Zhangbao  
CN103006562 
(A)  
2013  It is excellent in transdermal 
performance, drug release and has 
certain slow-release effect, and the 
preparation method is simple and 
convenient, low in cost and good in 
stability  
Ethosome preparation of male 
hormone  
Shu Meng; Jianxin Li; 
Yanmin Guan;  
CN102406605 
(A)  
2012  To improve transdermal transport 
of male hormone  
Paclitaxel ethosome gel and 
preparation method there of  
Jianping Tan; Lixin 
Jiang; Tanran Chang; 
Zhiwen Zhou  
CN102579323 
(A)  
2012  The action of stimulation to the skin 
can be reduced, and the 
percutaneous permeation effect is 
good.  
Acyclovir ethosome and 
preparation method there of 
21  
Xuewen Wu; Yan Xiong  CN102133183 
(A)  
2011  Acyclovir ethosome has high 
stability and narrow particle size 
distribution  
Podophyllotoxin ethosomes 
and preparation methods 
there of 22  
Nianping Feng; Yanyan 
Yu; Jihui Zhao; Haiting 
Weng; Xiaoqin Shi  
CN102144972 
(A)  
2011  The invention discloses two 
preparation methods for the 
podophyllotoxin ethosomes  
Terbinafine compositions for 
onychomycosis treatment  
E.Touitou  WO20100867
23A1  
2010  Novel terbinafine topical 
compositions for the treatment of 
nail onychomycosis  
 
CONCLUSION 
Ethosomes are a pioneering platform technology that offers 
modified delivery systems to meet the necessary criteria 
for efficient and safe drug administration into and across 
the skin. Considerable research has been conducted to 
characterize this novel non-invasive carrier. Because of 
their composition, ethosomes are soft vesicles, which 
penetrate through the SC lipids and transport the active 
agent to the deep layers of the skin. These vesicular 
systems were proven efficient for dermal and transdermal 
delivery of various energetic agents in animals and 
humans. Among the many areas where ethosomal 
transdermal delivery could be helpful are Parkinson’s 
disease, hormone replacement therapy, cardiovascular 
treatments and rheumatic disorders. Delivery of antibiotics 
and antiviral to the deep layers of the skin and drugs for 
management of alopecia to the hair follicles by an 
ethosomal carrier could greatly increase drug treatment 
competence and patient convenience. The highly 
competent delivery, together with its lack of toxicity and 
preparation simplicity, makes this system a promising 
candidate for the administration of chemical and biological 
compounds. Such developments may further increase the 
field of transdermal applications. 
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